MedTrace Logo

EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer

NCT06011772 · Status: ACTIVE_NOT_RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2026-03-11

No results posted yet for this study

Summary

The purpose of this study is to determine the immunogenicity of the CIMAvaxEGF® vaccine (that is, its effectiveness in inducing an anti-tumor immune response) in patients with metastatic KRAS/NRAS/BRAF wild-type gene colorectal cancer, when given in combination with standard therapies used in the treatment of advanced colorectal cancer.

Conditions

  • Colo-rectal Cancer

Interventions

BIOLOGICAL

Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine

Given IM

DRUG

Leucovorin

Given IV

DRUG

Oxaliplatin

Given IV

DRUG

Fluorouracil

Given IV

BIOLOGICAL

Bevacizumab

Given IV

DRUG

Irinotecan

Given IV

BIOLOGICAL

Cetuximab

Given IV

PROCEDURE

Metastasectomy

Undergo metastasectomy

PROCEDURE

Biospecimen collection

Undergo collection of blood samples

PROCEDURE

Computed Tomography

Undergo CT

BIOLOGICAL

Panitumumbab

Given IV

Sponsors & Collaborators

  • Roswell Park Cancer Institute

    lead OTHER

Principal Investigators

  • Anuradha Krishnamurthy, MBBS · Roswell Park Comprehensive Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-18
Primary Completion
2026-02-05
Completion
2026-12-04
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06011772 on ClinicalTrials.gov